Edwin Ostrin is a Respiratory physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 197 publications with 3,946 citations (h-index 32).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingMedicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Corticosteroid100%Trelegy Ellipta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort
University of Tx Md Anderson Can Ctr
FY2025$525,013U01CA295902
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials
Journal of Thoracic Oncology
2025 - Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept
Cell Reports Medicine
2024 - Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non–Small Cell Lung Cancer. An Official American Thoracic Society Research Statement
American Journal of Respiratory and Critical Care Medicine
2024 - Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations
Journal of Thoracic Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”